Discordant predictions of residual activity could impact dolutegravir prescription upon raltegravir failure by Theys, Kristof et al.
!Title:' Discordant! predictions! of! residual! activity! could! impact! dolutegravir! prescription! upon!
raltegravir!failure!
'




a.!KU!Leuven! M!University!of!Leuven,!Department!Microbiology!and! Immunology,!Rega! Institute! for!
Medical!Research,!BM3000!Leuven,!Belgium!!








Corresponding+ author*:# Kristof# Theys;# Clinical# and# Epidemiological# Virology,# Rega# Institute# for#
Medical(Research,(Department(of(Microbiology(and( Immunology,(KU(Leuven;(Minderbroedersstraat(










143,%148%and%155,!and! interpreted( into( clinically( informative( resistance( levels(using!genotypic'drug'
resistance) interpretation) systems) ANRS% v24," HIVdb" v7.0" and" Rega" v9.1.0,! and$ instructions$ of$
dolutegravir! use$ as$ approved$ by$ the$ Food$ and$ Drug$ Administration$ and$ the$ European) Medicines)
Agency.!
Results:"In#216#HIVM1"patients"failing"raltegravirMtherapy,(87%$patients&displayed&mutations&associated)
with% resistance% towards% integrase% inhibitors.% A! total% of% 141% unique% mutational% patterns% were%
observed," with" N155H" (25.4%)," Q148H" (16.2%)" and" Y143R" (8.3%)" the" most" prevalent" signature"
mutations."The$Q148$pathway&occurred&almost&exclusively&in&HIVM1"subtype"B"viruses."Concordances*
in#predicted(dolutegravir,susceptibility,scores,among,5,systems,were,obtained,in,57.8%,of,patients,,
and$concordant$ intermediate$ resistant$and$concordant( resistant( scores(were(only(observed( in(6.5%%
and$0.9%!of#patients,"respectively."However,"systems"individually"scored"higher"levels"of"dolutegravir"
intermediate) resistance) and) resistance,* ranging* from* 4.2%% to% 10.2%% and% from% 14.8%% to% 22.7%% of%
patients,"respectively."A!consensus'on'interpreting(the(extent(of(residual(activity(was(lacking(in(34.7%(
of#patients(and(was(highly(resistance(pathwayMspecific.(!
Conclusions:" Dolutegravir" may" potentially" be" effective" in" the" majority" of" HIVM1" patients" failing"





Virus!type!1! (HIVM1),!potent!virological!suppression!by!antiretroviral! treatment! (ART)!remains!a!key!
mechanism!to!reduce!HIVM1!morbidity!and!mortality!as!well!as!to!prevent!further!epidemic!spread.!
Therapeutic! options! for! HIVM1! infection! strongly! enlarged! with! the! introduction! of! integrase! (IN)!
strand! transfer! inhibitors! (INSTIs)! into! clinical! practice.! This! latest! approved! drug! class! includes!





clinical! benefit! of! dolutegravir! following! firstMgeneration! INSTIMcontaining! regimen! failure! is!
supported! by! observations! of! retained! in# vitro! activity! against! some! raltegravirM! or! elvitegravirM
resistant! isolates![5M8].!Furthermore,!the!VIKINGM3!and!VIKINGM4!clinical!trials!assessed!dolutegravir!
efficacy! in! HIVM1! patients! with! a! history! of! genotypic! evidence! of! multiMclass! resistance! including!
INSTIs![9M11].!!
The! decision! to! use! dolutegravir! in! this! setting! should! be! informed! by! genotypic! drug! resistance!
testing!of!the!IN!coding!region![1M4].!Based!on!genotypic!and!phenotypic!studies,!viral!adaptation!to!
INSTI! selective! pressure! occurs! along! distinct! but! not! mutually! exclusive! pathways,! which! are!
characterized! by! signature! resistanceMassociated!mutations! (RAMs)! evolving! into! complex! patterns!
during! prolonged! drug! exposure! [12M20].! However,! a!wide! spectrum!of! identified! INSTI! RAMs! and!






The! objective! of! this! study! was! to! determine! the! extent! of! disagreement! in! predicted! residual!
dolutegravir!activity!in!order!to!improve!the!interpretation!of!genotypic!dolutegravir!resistance.!!The!
identification! of! individual! mutational! patterns! associated! with! uncertainty! among! HIVM1! expert!






sequence! was! retained! when! multiple! isolates! of! a! patient! were! available.! Viral! subtyping! was!
performed!by!the!Rega!subtyping!tool!v3.0![23].!
INSTI! RAMs! were! defined! by! their! presence! in! the! IASMUSA! 2014! list! [24],! in! drug! resistance!
interpretation! systems!ANRS!v24! [25],!HIVdb!v7.0.1! [26]! and!Rega! v9.1.0! [27],! or! in! FDA!and!EMA!
package! inserts!of! the!three! INSTIs! [3,4,28,29].!The!following!exhaustive!mutation! list!was!derived:!
S17N,! H51Y,! T66AIK,! L68IV,! L74IM,! E92GQV,! Q95KLR,! T97A,! H114Y,! G118R,! F121CY,! T124A,!
E138ADKT,! G140ACS,! Y143ACGHKRS,! P145S,! Q146IKLPR,! S147G,! Q148EGHKR,! V151AIL,! S153AFY,!
M154I,!N155HST,!K156N,!E157PQ,!G163EKQRS,!V165I,!H183P,!G193ER,!T206S,!Y226CDFH,!S230NR,!
D232N,!R263K!and!V281M,!with! T66AIK,! E92GQV,!G118R,! F121Y,! E138K,!G140ACS,! Y143ACHGKRS,!
P145S,!Q146ILPR,!S147G,!Q148EGHKR,!V151L,!S153Y,!N155HST,!E157Q!and!R263K!defined!as!major!
mutations!against!at!least!one!of!the!three!INSTI!approved!for!clinical!use.!In!particular,!the!following!
40!mutations!were! listed! to!be!associated!with! reduced! susceptibility! to!dolutegravir:!H51Y,! T66K,!
L74IM,!E92GQV,!Q95L,!T97A,!G118R,!F121Y,!T124A,!E138ADKT!G140ACS,!Y143CHR,!Q148HKR,!V151L,!
S153FY,! M154I,! N155H,! E157PQ,! G163EKQRS,! G193ER,! R263K.! Polymorphic! INSTI! resistanceM
associated!mutations!were!identified!based!on!Rhee!et!al.![30].!
Mutation! patterns!were! categorized! into! 6! groups! according! to!mutations! at! raltegravir! signature!
!positions!143,!148!and!155! [31],!and!assigned!clinically! informative! resistance! levels!of! susceptible!
(S),! intermediate!resistant! (IR)!or!resistant! (R),!as!scored!by!ANRS,!HIVdb!and!Rega.!For!HIVdb,! five!
level!scores!were!simplified!to!three!levels:!susceptible!and!potential!lowMlevel!resistant!were!scored!
as!susceptible,!lowMlevel!and!intermediate!resistant!were!scored!as!intermediate!resistant!and!highM
level! resistant!as!resistant.!As! independent!data!of! in#vivo!dolutegravir!response!data!from!outside!
clinical! trials! is! still! limited,! two! additional! categorization! schemes!were! derived! from! information!
provided! in!the!FDA!and!EMA!package! inserts! [3,4].!According!to!FDA,!poor!virologic!response!was!
observed! in! VIKINGM3! study! patients! displaying! Q148HR! and! at! least! 2! mutations! of! L74IM,!
E138ADKT,! G140AS,! Y143HR,! E157Q,! G163EKQRS! or! G193ER,! or! in! patients! having! at! least! 3!
mutations! of! L74IM,! E138ADKT,! G140AS,! Y143HR,! Q148HR,! E157Q,! G163EKQRS! or! G193ER!
(respectively!18%!and!25%!of!patients!obtained!<50!RNA!copies/ml!at!week!24),!and!therefore!these!
mutational!patterns!were!categorized!as!resistant!in!this!study.!A!diminished!response!was!observed!
in! patients! displaying! Y143CHR! without! any! Q148! mutation! or! displaying! Q148HR! and! G140AS!
without! any! other! INSTI!mutation! (<50! RNA! copies/ml! at! week! 24! in! 56%! of! patients),! and! these!




resistant! for! any! Q148! mutation! and! 1! mutation! of! L74I,! E138AKT! or! G140ACS! (65%! of! patients!
obtained! <50! RNA! copies/ml! at! week! 24)! and! into! susceptible! for! any! other! combination! of!




they! all! scored! identical! resistance! levels,! and!was! defined! discordant! otherwise.! A! prediction! for!
dolutegravir! was! defined! concordant! among! the! three! interpretation! algorithms! and! the! two!









FortyMthree! of! the! 79! defined! INSTI! RAMs! (54%)! were! detected! in! 216! raltegravirMexperienced!
patients! (Figure! 1).! A! total! of! 188!HIVM1! sequences! (87%)! carried! at! least! one! INSTI!mutation! and!
evidence! of! a!major! INSTI!mutation!was! observed! in! 132! patients! (61%).! A! signature!mutation! at!
positions! 143,! 148! or! 155! was! observed! in! 120! patients! (57%).! The! signature! mutation! N155H!
displayed! the! highest! prevalence! (25.4%),! followed! by! Q148H! (16.2%)! and! Y143R! (8.3%).! Most!
prevalent!major! INSTI!RAMs!were!G140S! (18.5%),! E157Q! (6.9%)! and!E92Q! (4.6%),! of!which!G140S!
was!mainly!associated!with!Q148H!(88%),!while!other!INSTI!mutations!T124A!(31.4%),!S17N!(25.2%),!
T206S!(25.0%),!T97A!(15.2%),!V151I!(11.5%)!and!K156N!(9.7%)!prevailed.!
AlgorithmMspecific! resistance! levels! for! raltegravir! were! for! ANRS! (S=41.7%,! R=58.3%),! HIVdb!
(S=36.6%,! I=7.9%,!R=55.6%)!and!Rega! (S=42.6%,! I=5.1%,!R=52.3%)! (Figure!2A).!Predicted!genotypic!
susceptibility! levels! for! raltegravir! displayed! 8.8%! discordances! between! ANRS,! HIVdb! and! Rega,!
while! concordant!predictions!were! resistant! (52.3%),! intermediate! resistant! (2.3%)!and! susceptible!
(36.6%)! (Figure! 2C).! SystemMspecific' resistance! levels! for! dolutegravir! (Figure! 2B)! were! for! ANRS!
(S=75.9%,! I=14.8%,!R=9.3%),!HIVdb!(S=69.0%,! I=22.7%,!R=8.3%),!Rega!(S=70.4%,! I=19.4%,!R=10.2%),!
FDA! (S=69.0%,! I=20.8%,!R=10.2%)!and!EMA! (S=79.6%,! I=16.2%,!R=4.2%).!Discordances! in!predicted!
dolutegravir!activity!between!the!three!interpretation!algorithms!and!the!two!derived!categorization!
schemes! was! observed! in! 34.7%! of! patients,! while! 57.8%,! 6.5%! and! 0.9%! of! the! sequences! were!
!concordantly! scored! susceptible,! intermediate! resistant! and! resistant,! respectively! (Figure!2C).! The!







Y143S! (4.2%).! These!mutations!were!accompanied!by!T97A! (75.0%),! T206S! (37.5%),! L74M! (37.5%),!
T124A!(16.7%),!G163R!(16.7%)!and!S230R!(16.7%).!An!S!score!was!assigned!in!69.2%!of!all!individual!











(n=1),! E138K! (n=1),! E157Q! (n=5)! and! R263K! (n=3).! Finally,! no! INSTI!mutation! was! observed! in! 20!
patients!(9.3%).!!
!
Disagreement! in! estimated! activity! of! dolutegravir! between! the! scoring! systems! was! further!
evaluated!by! the! extent! of! discordant! predictions! for! each!of! the! six! patient! groups! (Figure! 3! and!
!Table! 1).! Patients! displaying! the! N155H! pathway! showed! a! high! level! of! concordant! susceptible!
scores! (66%)! but! a! consensus!was! not! detected! for! the! remaining! 34%! of! patients.! High! levels! of!
discordant! predictions!were! observed! for! patients! displaying! the! Y143!pathway! (95.8%),! the!Q148!
pathway! (62.5%)! and!multiple! signature!mutations! (88.9%),! resulting! in! low! levels! of! concordantly!
estimated!susceptible!scores.!The!Q148!pathway!was!concordantly!estimated!intermediate!resistant!
or! resistant! in! 35.0%!and!2.5%!of! patients! respectively.! The!patient! group!with!no! signature! INSTI!
RAMs!showed!a!high!percentage!agreement!in!susceptible!scores!by!all!algorithms!(96.1%).! !For!14!
patients! (6.5%),!all! three! levels!of!predicted!drug!susceptibility! (S,! IR!and!R)!were!assigned,!with! in!
particular! the! Y143! patient! group! (16.7%),! the! N155H! group! (8.5%)! and! patients! with! multiple!




patients! without! any! signature! INSTI! mutations.! High! values! of! chanceMcorrected! agreement!
measures!were!only!observed!for!the!patient!group!with!multiple!signature!mutations!(α!=!0.88)!and!
for! the!patient!group! that! lacked!a! signature! INSTI!mutation! (α!=!0.99),!when! limited! to! the! three!
algorithms!(Table!1).!!
!
Subtype! B! viruses! were! detected! in! 71%! of! patients.! Predicted! genotypic! susceptibility! levels! of!




scores!were!not! differently! prevalent! (37.9%! vs! 27.0%,! pMvalue! =! 0.16)! for! all! five! systems.! Similar!
findings! were! obtained! for! the! three! expertMbased! algorithms! only,! with! respect! to! concordant!
susceptible!(56.9%!vs!84.1%,!pMvalue!=!0.002)!and!discordant!scores!(26.1%!vs!15.9%,!pMvalue!=!0.15).!





last! decades,! HIVM1! inhibitors! that! retain! activity! against! drug! resistant! HIVM1! variants! remain! a!
keystone! in! the! lifeMlong! treatment! of!HIVM1!patients.!Due! to! therapeutic! failure,! the! treatment!of!
HIVM1! infected! patients! is! generally! characterized! by! multiple! consecutive! drug! regimens.! The!
emergence!of!drugMresistant!HIVM1!variants! impairs!the!effectiveness!of!similar!HIVM1! inhibitors!and!
complicates!treatment!sequencing!strategies!as!resistance!profiles!can!be!shared!between!inhibitors!
from! the! same! drug! class! [33].! In! clinical! practice,! the! management! of! HIVM1! drug! resistance!
constitutes! an! essential! part! of! longMterm! successful! treatment! of! HIVM1! infection.! However,! the!
translation! of! genotypic! drug! resistance! into! clinical! implications! is! a! challenging! task,! and! drug!
resistance!interpretation!systems!are!widely!used!to!assist!clinicians!in!the!management!of!individual!
patients! for!whom! treatment! switches! are! indicated.!Uncertainty! in!predicted!dolutegravir! activity!
could! have! implications! for! genotypeMguided! treatmentMdecisions.! Hence,! information! on! the!
mutational! patterns! underlying! discordances! in! estimated! outcome! serves! as! a! valuable! prior! for!




algorithms,! widely! used! in! the! clinical! management! of! HIVM1! infected! patients.! Additionally,! two!
categorization! schemes! were! derived! from! the! company! package! inserts,! given! that! dolutegravir!
response!data!outside!the!VIKING!clinical!trials! is!not!abundantly!available!to!date.!Based!upon!our!
study!and!others,!dolutegravir!may!be!potentially!effective!in!the!majority!of!HIVM1!patients!failing!a!
raltegravirMcontaining! regimen! [6,7,9,15].! However,! a! consensus! on! interpreting! the! extent! of!
!residual!activity!among!the!five!systems!was!lacking!in!a!large!proportion!of!patients!and!showed!a!
resistance! pathwayMspecific! pattern,! which! could! lead! to! uncertainty! in! individual! patient!
management.! Although! concordant! intermediate! resistance! and! resistance! scores! were! only!
obtained!in!7.4%!of!all!patients,!individual!interpretation!systems!scored!these!resistance!levels!more!
often,! from! 20.4%! for! the! EMA! scheme! to! 31%! for! HIVdb! and! FDA! scheme.! The! highest! levels! of!
disagreement!were!observed!for!Y143!and!Q148!groups!and!for!patterns!including!multiple!signature!
mutations.! The! Y143! group! showed! susceptible! scores! for! almost! 70%! of! all! predictions,! but!
concordant! susceptibility! scores! were! only! obtained! for! 4%! of! predictions.! The! intermediate!
resistance!score!that!was!triggered!by!the!FDA!scheme!when!Y143CHR!was!present!in!absence!of!any!
Q148! mutation! mainly! caused! the! high! level! of! discordance! in! this! group.! The! Q148! group! was!
predicted!to!be!most!affected,!with!only!3%!of!all!individual!predictions!assigning!a!susceptible!score,!
in! line!with!reports!that!the! largest! impact!on!viral!susceptibility!and!virological!response! in!clinical!
trials! was! observed! for! study! patients! with! Q148! mutations! in! association! with! other! INSTIs!
resistanceMassociated! mutations! (RAMs)! [9,10]." This" group! also! showed! a" high! percentage) of!
discordance!between&systems."The$N155H$pathway$showed$a$high$proportion$of$ individual$S$scores!
and$lower$discordance$rates.!Similar'findings'were!also%observed%for%patients!that$did$not$display$any$
of# the" raltegravir" signature"mutations." However," 3" patients!within& this& group& displayed& the&R263K%
mutation," which" has$ been$ reported$ to$ be$ selected$ in# vitro# and! in# vivo! by! both! raltegravir) and)
dolutegravir! [17,34]." This" nonMpolymorphic* mutation! is# scored# highMlevel$ resistant$ by$ ANRS$while!





When! the!analysis!was! limited! to! the! three! interpretation!algorithms!only,! in!order! to!account! for!
possible!distortions!resulting!from!the!inclusion!of!the!two!categorization!schemes,!the!frequency!of!
!discordant! predictions! decreased! from! 34.7%! to! 23.1%,! while! concordant! predictions! were! more!
observed! for! all! three! resistance! scores.! The! finding! that! raltegravir! activity! was! discordantly!
predicted!in!merely!8.8%!of!patients!could!highlight!the!lack!of!sufficient!knowledge!on!dolutegravir!
resistance,! and! supports! the! study! rationale!of! including! the!package! insertMderived! categorization!
schemes.! ! The!Y143,!Q148!and!multiple! signature!mutation!patient!groups! showed! lower! levels!of!
discordant!predictions,!although!remaining!above!40%!for!the!Y143!and!Q148!groups.!!!
!
The! extent! of! discordant! predictions! between! the! systems! was! examined! using! two! different!
measures,!the!percentage!of!agreement!and!the!Krippendorff's!alpha.!The!latter!coefficient!corrects!
for! agreement! occurring! by! chance! and! accounts! for! ordinal! resistance! scores.! The! highest! alpha!
values!were! obtained! for! the! patient! group!with!multiple! signature!mutations! and! for! the! patient!
group!without!any!signature!mutation.!Differences!in!agreement!between!the!two!measures!can!be!
expected,! given! that! Krippendorff’s! alpha! calculates! disagreements! among! raters! instead! of! the!
percentage! of! agreement! and! applies! a! different! weighting! for! more! distant! scores! (susceptible!





Several' INSTI'RAMs'were'highly'prevalent' in'our' study'population'but$ they$ represented( consensus(
residues' in' specific' subtypes! (S17N,& T124A,! T206S)! or# known# polymorphisms# in# treatmentMnaive&
patients((T97A,!V151I!and!K156N)![22]."The"predominant"presence"of"subtype"B"viruses"in"the"Q148"
pathway' has' been' reported! before! [15],& and& this& preference! is# most% likely% explained% by% a! lower&
genetic'barrier'for$ INSTI%RAMs!at#position#140,"which"were"almost'exclusively!found& in#combination#
with! raltegravir) signature*mutations!Q148." Because' of' a' different' codon' usage,' subtype' B' viruses'
require& only& a& single& nucleotide& substitution& for& the& change& G140S& while& two& substitutions! are$






investigated.! Our! study! used! three! wellMacknowledged! genotypic! resistance! interpretation!
algorithms,!but!other!available!HIVM1! interpretation! systems!should!be! investigated!as!well! to! fully!
characterize! flaws! in! the! translation! of! observed! resistance! to! clinically! informed! treatment!
decisions.! All! patients! in! our! study! were! experienced! with! other! drug! classes! before! raltegravir!
treatment,!reflecting!that!raltegravir!was!initially!limited!to!therapyMexperienced!patients!with!multiM
class!drug!resistance!against!reverse!transcriptase!and!protease!inhibitors.!To!date,!raltegravir!is!also!





In! conclusion,! despite! extensive! reports! on! INSTI! resistance! development,! our! findings! strongly!
indicate! that! further! research! is! necessary! for! a! better! understanding! of! genotypic! resistance!
towards!dolutegravir,! in!particular! for!mutation!pathways! involving!positions!143!and!148.!Besides!
collecting!and!analyzing!cohort!data,!open!access!to!raw!data!from!large!clinical!trials!could!enable!
independent!reManalysis!and!might!eventually!improve!personalized!treatment!of!HIVM1!patients.' !
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Figure' 2.' Predicted' genotypic' susceptibility' scores' in' HIVS1' sequences' obtained' after' raltegravir'
failure.!A.'and'B.'Frequency!of! susceptible! ,! intermediate! resistant! ,! and! resistant! ! scores! for!
raltegravir!(RAL)!(A)!and!dolutegravir!(DTG)!(B),!interpreted!with!rules!derived!from!ANRS!v24,!HIVdb!
v7.0.1,! Rega! v9.1.0,! FDA! and! EMA!package! inserts,! as! defined! in! text.!C.'Frequency! of! concordant!
susceptible! ,! intermediate! resistant! ,! resistant! ! and! discordant! !! scores! between! drug!
resistance!interpretation!systems!ANRS!v24,!HIVdb!v7.0.1!and!Rega!v9.1.0,!for!RAL!and!DTG!(DTG3),!
and!between!drug!resistance! interpretation!systems!ANRS!v24,!HIVdb!v7.0.1,!Rega!v9.1.0,!FDA!and!
EMA! package! insertMderived! categorization! schemes! for! DTG! (DTG5).! For! ANRS! v24,! only! RAL!
resistanceMlevels! S! and! R! are! defined,! and! considered! concordant! with! I! scores! from! the! other! 2!
systems.!
'
Figure' 3.! The' frequency' of' concordant' and' discordant' dolutegravir' resistance' scores' in' HIVS1'
sequences' obtained' after' raltegravir' failure.! ! Interpretation! of! drug! activity! was! performed! with!
rules!derived!from!ANRS!v24,!HIVdb!v7.0.1,!Rega!v9.1.0,!FDA!and!EMA!package!inserts,!as!defined!in!
text.! The! number! of! unique! mutational! patterns! are! displayed! and! categorized! according! to! the!
presence! of! signature! mutations! Y143CHRS,! Q148HKR! and/or! N155H.! Concordant! susceptible! ,!
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Pathway' Scorea' Five'systemsb' Three'algorithmsc'
! ' Frequency'(%)' Agreement'(α)' Frequency'(%)' Agreement'(α)'
Y143'






















S' 96.1! 0.48! 96.1! 0.99!
I' M! M!
R' M! M!
D' 3.9! 3.9!
!
a!Concordant!resistance!level!or!discordant!score:!S!=!concordant!susceptible;!I!=!concordant!intermediate!resistance;!R!=!
concordant!resistance;!D!=!discordant!!
b!!Concordant!when!all!5!systems!(3!expertMbased!algorithms!ANRS,!Rega!and!HIVdb,!and!2!categorization!schemes!FDA!and!
EMA)!scored!identical!resistance!levels.!!
c!Concordant!when!all!3!expertMbased!algorithms!ANRS,!Rega!and!HIVdb!scored!identical!resistance!levels.!
!
